Transforming obesity treatment
Developing first-in-class, adipose-targeted RNA therapies that address the biology of cardiometabolic diseases
AI-Enabled Discovery
By combining deep human genetics, epigenetics, and proprietary adipose-targeted siRNA technology we're developing novel therapies with the potential to deliver durable weight loss, preserve lean mass and improve tolerability.
A New Approach to Treating Obesity
Today's obesity medicines have transformed patient care, but important unmet needs remain, including gastrointestinal side effects, loss of lean mass including muscle and bone, weight regain after treatment discontinuation and the need for frequent dosing.
Moonwalk is developing therapies that directly target adipose biology through entirely new, non-appetite suppressing mechanisms designed to:
- Preserve lean muscle while reducing fat mass
- Improve tolerability
- Enable infrequent dosing: quarterly or twice yearly
- Complement or provide an alternative to incretin therapies
Investors
